
Sign up to save your podcasts
Or


In today’s episode of Phagecast, we interview Célia Pas from ACD Pharma, to dive into the world of tailocins and how they can be engineered as highly specific antibacterial tools, work that she carried out as PhD student in Yves Briers lab.
We start with an introduction to Célia and her research environment, before moving into a detailed discussion of her recent work using a VersaTile engineering approach to reprogram the specificity of R2-type tailocins.
Throughout the episode, we cover:
What tailocins are, how they differ from phages and endolysins...
Why targetting Gram-negative pathogens like E. coli and Klebsiella pneumoniae.
What the VersaTile technique is, how it works, and why it offers a flexible and powerful platform for engineering tailocin specificity... and much more!
We close the episode with Célia’s personal experience as a PhD student, discussing the challenges of this work, what she is most proud of, and her transition toward industry—along with practical advice for early-career researchers considering similar paths.
By News and interviews on the phage field.5
33 ratings
In today’s episode of Phagecast, we interview Célia Pas from ACD Pharma, to dive into the world of tailocins and how they can be engineered as highly specific antibacterial tools, work that she carried out as PhD student in Yves Briers lab.
We start with an introduction to Célia and her research environment, before moving into a detailed discussion of her recent work using a VersaTile engineering approach to reprogram the specificity of R2-type tailocins.
Throughout the episode, we cover:
What tailocins are, how they differ from phages and endolysins...
Why targetting Gram-negative pathogens like E. coli and Klebsiella pneumoniae.
What the VersaTile technique is, how it works, and why it offers a flexible and powerful platform for engineering tailocin specificity... and much more!
We close the episode with Célia’s personal experience as a PhD student, discussing the challenges of this work, what she is most proud of, and her transition toward industry—along with practical advice for early-career researchers considering similar paths.